Dendreon Corp (DNDN) 2.07 $DNDN
Dendreon Names W. Thomas Amick President and Chief Executive Officer
Business Wire - Wed Jul 30, 3:02PM CDT
Dendreon Corporation (Nasdaq
NDN) today announced that its board of directors has appointed W. Thomas Amick as president and chief executive officer, effective immediately. Mr. Amick has also been appointed to the Company's board of directors. Mr. Amick succeeds John H. Johnson, who previously announced his plans to step down as president and chief executive officer for personal reasons. Mr. Johnson will work with Mr. Amick through August 15, 2014 to ensure a smooth transition.
Are Cancer Vaccines Worth an Investment?
Seth Robey, The Motley Fool - Motley Fool - Thu Jul 10, 8:30AM CDT
A report from Boston's Decision Resource Group last month suggested that the immuno-oncology drugs garnering excitement from patients, doctors, and investors could balloon into a $9 billion market by 2022. That would represent a 23.8% CAGR from the...
Technical Data on Health Care Sector Equities -- Research on Achillion Pharma, Novavax, Dendreon, and Exelixis
PR Newswire - Thu Jul 10, 6:00AM CDT
On Wednesday, July 09, 2014, the NASDAQ Composite ended at 4,419.03, up 0.63%, the Dow Jones Industrial Average advanced 0.47%, to finish the day at 16,985.61, and the S&P 500 closed at 1,972.83, up 0.46%. The gains were broad based with nine out of ten sectors ending the session in positive. The S&P 500 Health Care Sector Index ended the day at 712.05, up 0.38%, with the index advancing 5.76% in the previous three months. Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Novavax Inc. (NASDAQ: NVAX), Dendreon Corp. (NASDAQ: DNDN) and Exelixis Inc. (NASDAQ: EXEL). Free technical research on ACHN, NVAX, DNDN and EXEL can be downloaded upon signing up at:
3 Reasons to Buy Medivation Inc.
George Budwell, The Motley Fool - Motley Fool - Mon Jul 07, 3:30PM CDT
The biotech industry has ballooned in terms of market value over the past two years. As a result, we have seen dozens of IPOs, creating a diverse population of companies that can be quite a challenge to follow in their entirety. So it's not...
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/465jcl/transitional_cell) has announced the addition of the "Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Amgen Inc. - Sanofi - Daiichi Sankyo Company, Limited - Novartis AG - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Dendreon Corporation - Cadila Pharmaceuticals Ltd. For more information visit http://www.researchandmarkets.com/research/46...ional_cell
Is There Any Hope for Dendreon?
Alexander Maxwell, The Motley Fool - Motley Fool - Wed Jul 02, 4:01PM CDT
Dendreon Corporation shareholders have been on a rollercoaster over the past few years. Dendreon got their lead product Provenge approved for use in metastatic castration-resistant prostate cancer, but has been unable to profitably produce and...
Predicting Dendreon's Next CEO's Future
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Jun 30, 8:00PM CDT
Investors in Dendreon (Nasdaq: DNDN) are used to bad news, but a change in the CEO suite has given hope new leadership can turn around the struggling prostate cancer vaccine maker. Under his stewardship CEO John Johnson admirably cut costs, but...
Dendreon (DNDN) Stock Has Huge Short Interest: Time to Cover? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 8:58AM CDT
Dendreon (DNDN) Stock Has Huge Short Interest: Time to Cover?
Is Pfizer Putting the Car-T Before the Horse?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Thu Jun 19, 4:01PM CDT
Immuno-onocology is grabbing a large share of the headlines in oncology drug development these days and generating significant buzz for Big Pharma companies including Merck and Bristol-Myers Squibb . While Pfizer ...
Is Gene Therapy Medicine's Next Big Thing?
Todd Campbell, The Motley Fool - Motley Fool - Sat Jun 14, 12:05PM CDT
Bluebird Bio is a small company with big ideas. The clinical stage biotechnology company is researching novel treatments that seek to insert missing genes into patient stem cells. The science behind Bluebird's approach is so compelling that ...
Dendreon's CEO Departs at Critical Juncture - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 4:20PM CDT
Dendreon (DNDN) is now faced with a difficult time with its chief executive officer John H. Johnson deciding to step down on personal reasons.
Dendreon's CEO Exits: Is this the Beginning of the End?
George Budwell, The Motley Fool - Motley Fool - Tue Jun 10, 1:30PM CDT
Dendreon CEO and Chairman John Johnson has decided to call it quits after overseeing the biotechnology company's turbulent restructuring and attempted turnaround over the last two years. In 2012, Johnson took over for Mitchell Gold, who was unable...
Tuesday’s Top Biotech Stories: Achillion, Receptos, and Dendreon
Leo Sun, The Motley Fool - Motley Fool - Tue Jun 10, 8:08AM CDT
Let's take a closer look at three biotech stocks -- Achillion Pharmaceuticals , Receptos , and Dendreon -- which could all loom large in health care headlines this Tuesday morning. Achillion surges after the FDA lifts its clinical hold on...
Dendreon CEO Exits Ahead of Big Debt Payment
at The Street - Mon Jun 09, 3:38PM CDT
The desperate Dendreon debacle just descended into despondency with the abrupt departure of Chairman and CEO John Johnson, citing "personal reasons."
Dendreon Announces Leadership Transition
Business Wire - Mon Jun 09, 3:15PM CDT
Dendreon Corporation (Nasdaq NDN) today announced that John H. Johnson has informed the Board of Directors of his plans to step down as president and chief executive officer for personal reasons. Mr. Johnson has resigned from the Board, effective June 3, 2014, and the Board has elected Douglas G. Watson, Dendreon's lead independent director, as chairman of the Board.
Jim Cramer Talks Dendreon (DNDN), Salesforce.com (CRM) and Yelp (YELP)
at The Street - Mon Jun 09, 11:18AM CDT
TheStreet's Jim Cramer answers Twitter questions about Dendreon (DNDN), Salesforce.com (CRM) and Yelp (YELP).
Why Wall Street Hates Dendreon Corp.
George Budwell, The Motley Fool - Motley Fool - Fri Jun 06, 5:00PM CDT
A high short interest combined with low institutional ownership tends to be a fairly good sign that Wall Street isn't particularly thrilled with a company. Even so, Wall Street isn't always correct in predicting how a stock will perform over the long...
Biotech Dilemma: When a Loan Isn't Non-Dilutive
Brian Orelli, The Motley Fool - Motley Fool - Thu Jun 05, 7:41PM CDT
On this week's episode of Biotech Banter, we've got three related tweets about Retrophin 's announcement last week to take out a convertible note to help pay for its license of an orphan drug called Thiola from Mission Pharmacal. While...
Short Interest is Piling Up in Dendreon (DNDN) Stock, Time to Panic? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 02, 8:40AM CDT
Short Interest is Piling Up in Dendreon (DNDN) Stock, Time to Panic?
Johnson & Johnson Collaborates with Aduro BioTech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 30, 10:50AM CDT
Johnson & Johnson (JNJ) inked a global licensing deal with Aduro BioTech for developing new therapies to treat prostate cancer.
Dendreon Names W. Thomas Amick President and Chief Executive Officer
Business Wire - Wed Jul 30, 3:02PM CDT
Dendreon Corporation (Nasdaq
NDN) today announced that its board of directors has appointed W. Thomas Amick as president and chief executive officer, effective immediately. Mr. Amick has also been appointed to the Company's board of directors. Mr. Amick succeeds John H. Johnson, who previously announced his plans to step down as president and chief executive officer for personal reasons. Mr. Johnson will work with Mr. Amick through August 15, 2014 to ensure a smooth transition. Are Cancer Vaccines Worth an Investment?
Seth Robey, The Motley Fool - Motley Fool - Thu Jul 10, 8:30AM CDT
A report from Boston's Decision Resource Group last month suggested that the immuno-oncology drugs garnering excitement from patients, doctors, and investors could balloon into a $9 billion market by 2022. That would represent a 23.8% CAGR from the...
Technical Data on Health Care Sector Equities -- Research on Achillion Pharma, Novavax, Dendreon, and Exelixis
PR Newswire - Thu Jul 10, 6:00AM CDT
On Wednesday, July 09, 2014, the NASDAQ Composite ended at 4,419.03, up 0.63%, the Dow Jones Industrial Average advanced 0.47%, to finish the day at 16,985.61, and the S&P 500 closed at 1,972.83, up 0.46%. The gains were broad based with nine out of ten sectors ending the session in positive. The S&P 500 Health Care Sector Index ended the day at 712.05, up 0.38%, with the index advancing 5.76% in the previous three months. Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Novavax Inc. (NASDAQ: NVAX), Dendreon Corp. (NASDAQ: DNDN) and Exelixis Inc. (NASDAQ: EXEL). Free technical research on ACHN, NVAX, DNDN and EXEL can be downloaded upon signing up at:
3 Reasons to Buy Medivation Inc.
George Budwell, The Motley Fool - Motley Fool - Mon Jul 07, 3:30PM CDT
The biotech industry has ballooned in terms of market value over the past two years. As a result, we have seen dozens of IPOs, creating a diverse population of companies that can be quite a challenge to follow in their entirety. So it's not...
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/465jcl/transitional_cell) has announced the addition of the "Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Amgen Inc. - Sanofi - Daiichi Sankyo Company, Limited - Novartis AG - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Dendreon Corporation - Cadila Pharmaceuticals Ltd. For more information visit http://www.researchandmarkets.com/research/46...ional_cell
Is There Any Hope for Dendreon?
Alexander Maxwell, The Motley Fool - Motley Fool - Wed Jul 02, 4:01PM CDT
Dendreon Corporation shareholders have been on a rollercoaster over the past few years. Dendreon got their lead product Provenge approved for use in metastatic castration-resistant prostate cancer, but has been unable to profitably produce and...
Predicting Dendreon's Next CEO's Future
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Jun 30, 8:00PM CDT
Investors in Dendreon (Nasdaq: DNDN) are used to bad news, but a change in the CEO suite has given hope new leadership can turn around the struggling prostate cancer vaccine maker. Under his stewardship CEO John Johnson admirably cut costs, but...
Dendreon (DNDN) Stock Has Huge Short Interest: Time to Cover? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 8:58AM CDT
Dendreon (DNDN) Stock Has Huge Short Interest: Time to Cover?
Is Pfizer Putting the Car-T Before the Horse?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Thu Jun 19, 4:01PM CDT
Immuno-onocology is grabbing a large share of the headlines in oncology drug development these days and generating significant buzz for Big Pharma companies including Merck and Bristol-Myers Squibb . While Pfizer ...
Is Gene Therapy Medicine's Next Big Thing?
Todd Campbell, The Motley Fool - Motley Fool - Sat Jun 14, 12:05PM CDT
Bluebird Bio is a small company with big ideas. The clinical stage biotechnology company is researching novel treatments that seek to insert missing genes into patient stem cells. The science behind Bluebird's approach is so compelling that ...
Dendreon's CEO Departs at Critical Juncture - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 4:20PM CDT
Dendreon (DNDN) is now faced with a difficult time with its chief executive officer John H. Johnson deciding to step down on personal reasons.
Dendreon's CEO Exits: Is this the Beginning of the End?
George Budwell, The Motley Fool - Motley Fool - Tue Jun 10, 1:30PM CDT
Dendreon CEO and Chairman John Johnson has decided to call it quits after overseeing the biotechnology company's turbulent restructuring and attempted turnaround over the last two years. In 2012, Johnson took over for Mitchell Gold, who was unable...
Tuesday’s Top Biotech Stories: Achillion, Receptos, and Dendreon
Leo Sun, The Motley Fool - Motley Fool - Tue Jun 10, 8:08AM CDT
Let's take a closer look at three biotech stocks -- Achillion Pharmaceuticals , Receptos , and Dendreon -- which could all loom large in health care headlines this Tuesday morning. Achillion surges after the FDA lifts its clinical hold on...
Dendreon CEO Exits Ahead of Big Debt Payment
at The Street - Mon Jun 09, 3:38PM CDT
The desperate Dendreon debacle just descended into despondency with the abrupt departure of Chairman and CEO John Johnson, citing "personal reasons."
Dendreon Announces Leadership Transition
Business Wire - Mon Jun 09, 3:15PM CDT
Dendreon Corporation (Nasdaq
NDN) today announced that John H. Johnson has informed the Board of Directors of his plans to step down as president and chief executive officer for personal reasons. Mr. Johnson has resigned from the Board, effective June 3, 2014, and the Board has elected Douglas G. Watson, Dendreon's lead independent director, as chairman of the Board. Jim Cramer Talks Dendreon (DNDN), Salesforce.com (CRM) and Yelp (YELP)
at The Street - Mon Jun 09, 11:18AM CDT
TheStreet's Jim Cramer answers Twitter questions about Dendreon (DNDN), Salesforce.com (CRM) and Yelp (YELP).
Why Wall Street Hates Dendreon Corp.
George Budwell, The Motley Fool - Motley Fool - Fri Jun 06, 5:00PM CDT
A high short interest combined with low institutional ownership tends to be a fairly good sign that Wall Street isn't particularly thrilled with a company. Even so, Wall Street isn't always correct in predicting how a stock will perform over the long...
Biotech Dilemma: When a Loan Isn't Non-Dilutive
Brian Orelli, The Motley Fool - Motley Fool - Thu Jun 05, 7:41PM CDT
On this week's episode of Biotech Banter, we've got three related tweets about Retrophin 's announcement last week to take out a convertible note to help pay for its license of an orphan drug called Thiola from Mission Pharmacal. While...
Short Interest is Piling Up in Dendreon (DNDN) Stock, Time to Panic? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 02, 8:40AM CDT
Short Interest is Piling Up in Dendreon (DNDN) Stock, Time to Panic?
Johnson & Johnson Collaborates with Aduro BioTech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 30, 10:50AM CDT
Johnson & Johnson (JNJ) inked a global licensing deal with Aduro BioTech for developing new therapies to treat prostate cancer.
